Bristol Myers Squibb: Phase 3 CheckMate -901 Trial Fails To

NEW YORK CITY (dpa-AFX) - Bristol Myers Squibb (BMY) said the phase 3 CheckMate -901 trial, comparing Opdivo plus Yervoy to standard-of-care chemotherapy as a first-line treatment for patients

Related Keywords

Bristol Myers Squibb , Data Monitoring Committee , Myers Squibb , Bristol , Myers , Squibb , Hase , Checkmate , Trial , Nails , Feet , Primary , Ndpoint ,